BLRX vs. AADI, CLNN, APLM, NXTC, NRXP, BOLT, FIXX, CALC, GANX, and RMTI
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Aadi Bioscience (AADI), Clene (CLNN), Apollomics (APLM), NextCure (NXTC), NRx Pharmaceuticals (NRXP), Bolt Biotherapeutics (BOLT), Homology Medicines (FIXX), CalciMedica (CALC), Gain Therapeutics (GANX), and Rockwell Medical (RMTI). These companies are all part of the "pharmaceutical preparations" industry.
Aadi Bioscience (NASDAQ:AADI) and BioLineRx (NASDAQ:BLRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
BioLineRx received 492 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 73.43% of users gave BioLineRx an outperform vote while only 50.00% of users gave Aadi Bioscience an outperform vote.
BioLineRx has lower revenue, but higher earnings than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
BioLineRx has a net margin of 0.00% compared to BioLineRx's net margin of -270.04%. BioLineRx's return on equity of -52.53% beat Aadi Bioscience's return on equity.
52.1% of Aadi Bioscience shares are held by institutional investors. Comparatively, 1.6% of BioLineRx shares are held by institutional investors. 35.8% of Aadi Bioscience shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, BioLineRx had 3 more articles in the media than Aadi Bioscience. MarketBeat recorded 5 mentions for BioLineRx and 2 mentions for Aadi Bioscience. BioLineRx's average media sentiment score of 0.82 beat Aadi Bioscience's score of 0.27 indicating that Aadi Bioscience is being referred to more favorably in the media.
Aadi Bioscience has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Aadi Bioscience presently has a consensus target price of $24.67, indicating a potential upside of 1,255.31%. BioLineRx has a consensus target price of $21.00, indicating a potential upside of 3,275.12%. Given Aadi Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe BioLineRx is more favorable than Aadi Bioscience.
Summary
BioLineRx beats Aadi Bioscience on 11 of the 17 factors compared between the two stocks.
Get BioLineRx News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
Related Companies and Tools
